Prevalence of HPV and EBV infection and their relationship with the p53 and PCNA expression in oral carcinoma patients.

Dayahindara Veitía, Juan Liuzzi, Maira Àvila, Zoraya De Guglielmo, María Correnti

Abstract


Introduction: Infection caused by potentially oncogenic viruses, such as HPV and EBV, favors the role of certain oncoproteins that can induce dysplasias and malignant lesions. Objective: To evaluate the prevalence of HPV and EBV and their relation with the expression of p53 and PCNA in patients with oral carcinoma. Methodology: Twenty-seven oral squamous cell carcinomas (OSCC) were evaluated; DNA extraction was conducted using the QIAamp DNA mini kit; viral detection was obtained using the INNO-LiPA kit for HPV, and nested PCR was used for EBV. The evaluation of molecular markers was performed through immunohistochemical staining. Results: The mean age of the patients was 60.55±13.94 years, and 52% of these were female. Of the patients, 59% were tobacco users and 63% were alcohol consumers. HPV was detected in 70% of the patients with the predominance of genotype 16 (60%). As for EBV infection, it was observed in 59% of cases. p53 and PCNA immunopositivity corresponded to 44% and 59%, respectively. The tongue was the anatomical location with highest positivity for both viruses as well as for the expression of molecular markers. The 48% of the cases presented infection by both viruses. Conclusion: HPV and EBV infection together with the expression of p53 and PCNA were more frequently observed in advanced stages of the disease, suggesting a more relevant role in the progression than in tumor genesis.

Keywords


Carcinoma; VPH; VEB; p53; PCNA.

References


Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, Cuschieri K. Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer. 2012;106(2):358–65.

Secretaría de Salud (SSA). Registro Histopatológico de Neoplasias Malignas. Compendio/Mortalidad/Morbilidad/1999. México: Dirección General de Epidemiología; 1999.

Ministerio del Poder Popular para la Salud (MPPS). República Bolivariana de Venezuela Anuario de Mortalidad 2011. Caracas-Venezuela: Dirección General de Epidemiología; 2014.

Corball A. Tumores de Cavidad Oral. Cordoba-Argentina: FUNDACYC; 2016.

Kumar R, Rai AK, Das D, Das R, Kumar RS, Sarma A, Sharma S, Kataki AC, Ramteke A. Alcohol and Tobacco Increases Risk of High Risk HPV Infection in Head and Neck Cancer Patients: Study from North-East Region of India. PLoS One. 2015;10(10):e0140700.

Michmerhuizen NL, Birkeland AC, Bradford CR, Brenner JC. Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes Cancer. 2016;7(5-6):182–200.

Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693–703.

Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014;33(12):581–90.

Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, Abreo F, Rosenthal EL, Shi M, Guidry JT, Scott RS, Hutt-Fletcher LM, Nathan CA. Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med. 2015;44(1):28–36.

Liu Y, Lu Z, Xu R, Ke Y. Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology. Oncotarget. 2016;7(5):5852–64.

Tassone P, Old M, Teknos TN, Pan Q. p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol. 2013;49(8):733–7.

Poosarla C, Ramesh M, Ramesh K, Gudiseva S, Bala S, Sundar M. Proliferating Cell Nuclear Antigen in Premalignancy and Oral Squamous Cell Carcinoma. J Clin Diagn Res. 2015;9(6):ZC39–41.

Arreaza A, Correnti M, Avila M. Detección del virus Epstein-Barr en lesiones de liquen plano bucal. Act Odontol Venez. 2010;48(3):1–9.

Salazar CR, Smith RV, Garg MK, Haigentz M Jr, Schiff BA, Kawachi N, Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment. Head Neck Pathol. 2014;8(1):77–87.

Majchrzak E, Szybiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, Sowka M, Golusinski P, Malicki J, Golusinski W. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol. 2014;48(1):1–10.

Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence. 2015;6(3):244–8.

Vietía D, Liuzzi J, Ávila M, De Guglielmo Z, Prado Y, Correnti M. Human papillomavirus detection in head and neck squamous cell carcinoma. Ecancermedicalscience. 2014;8:475.

Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75.

Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) Head Neck Oncol. 2010;2:15.

Dufour X, Beby-Defaux A, Agius G, Lacau St Guily J. HPV and head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129(1):26–31.

Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS. 2010;118(6-7):510–9.

Koskinen WJ, Chen RW, Leivo I, Mäkitie A, Bäck L, Kontio R, Suuronen R, Lindqvist C, Auvinen E, Molijn A, Quint WG, Vaheri A, Aaltonen LM. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer. 2003;107(3):401–6.

Soares RC, Oliveira MC, de Souza LB, Costa Ade L, Pinto LP. Detection of HPV DNA and immunohistochemical expression of cell cycle proteins in oral carcinoma in a population of Brazilian patients. J Appl Oral Sci. 2008;16(5):340–4.

Polz-Gruszka D, Morshed K, Stec A, Polz-Dacewicz M. Prevalence of Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in oral and oropharyngeal squamous cell carcinoma in south-eastern Poland. Infect Agent Cancer. 2015;10:37.

Prabhu SR, Wilson DF. Evidence of Epstein–Barr Virus Association with Head and Neck Cancers: A Review. J Can Dent Assoc. 2016;82:g2.

Jibril FL, Aminu M, Jatau ED, Usman MA. Epstein–Barr Virus Antibody Titres in Head and Neck Cancer. Int J Sci Res. 2015;4(8):1841–5.

Veitía D, Liuzzi JF, Correnti M, Ávila M, De Guglielmo Z, Siso S, Da Cunha M. Detección de virus Epstein Barr en pacientes con cáncer de cabeza y cuello. Rev Venez Oncol. 2015;27(3):149–55.

Kis A. Prevalence of Epstein-Barr virus in oral squamous cell carcinoma and premalignat lesions, and the genetic and epigenetic aberrations of p14ARF and p16INK4A tumour suppressor genes in head and neck cancers. (Tesis Doctoral). University of Debrecen -Hungary: Doctoral School of Pharmaceutical Sciences; 2014.

Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, Abreo F, Rosenthal EL, Shi M, Guidry JT, Scott RS, Hutt-Fletcher LM, Nathan CA. Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med. 2015;44(1):28–36.


Full Text: PDF

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Corresponding: Facultad de Odontología, Universidad de Concepción, Chile. Roosevelt 1550, Concepción, Chile. Phone +56-41-2204232 - Fax +56-41-2243311- Mailbox 160-C, Concepción, Chile. E-mail journal@joralres.com.